期刊文献+

喹诺酮类抗菌药物的不良反应研究 被引量:4

Study on the Adverse Reactions of Quinolones
在线阅读 下载PDF
导出
摘要 目的研究喹诺酮类抗菌药物的不良反应,保障合理安全用药。方法回顾性分析2011年1月—2012年9月北京大学人民医院收治的181例有喹诺酮类抗菌药物不良反应病人的资料。结果左氧氟沙星的不良反应最高,加替沙星的不良反应最低,不良反应主要发生在神经系统、消化系统和皮肤及其附件上,结果差异有统计学意义(P<0.05),喹诺酮类抗菌药物的不良反应与年龄、给药方式和药物不良反应出现时间密切相关,结果差异有统计学意义(P<0.05),喹诺酮类抗菌药物的不良反应与性别无关,结果差异无统计学意义(P>0.05)。结论加大使用喹诺酮类抗菌药物的监测力度,保证药物使用的安全性。 Objective To study the adverse reactions of quinolones so as to ensure reasonable medication. Methods The data of 181 cases of patients with quinolone antibacterial drug adverse reactions admitted in Peking University People's Hospital from January, 2011 to September, 2012 were analyzed retrospectively. Results Levofloxacin had the highest incidence of adverse reac- tions and gatifloxacin had the lowest and the adverse reactions mainly occurred in the nervous system, digestive system and skin and its appendages, the results were statistically significant (P〈0.05). The incidence of adverse reactions of quinolone antibacterial drugs is closely related to age, the mode of administration, and the occurrence time of adverse reactions, the result was statistically significant (P〈0.05). The adverse reactions of quinolone antibacterial drugs had nothing to do with the sex, the result was not sta- tistically significant (P〉0.05). Conclusion In order to ensure the safety of drug use, the monitoring for the use of quinolone an tibacterial drugs should be strengthened.
作者 吕素芹
出处 《中外医疗》 2013年第32期2-3,共2页 China & Foreign Medical Treatment
关键词 喹诺酮类抗菌药物 不良反应 用药安全 Quinolone antibacterial drugs Adverse reaction Drug safety
  • 相关文献

参考文献5

二级参考文献21

  • 1Yamaguchi H, Kawai H, Matsumoto T, et al. Post-marketing surveillance of the safety of levofloxacin in Japan [ J ]. Chemotherapy, 2007, 53 ( 2 ) : 85-103.
  • 2Owens RC Jr, Ambrose PG. Antimicrobial safety : focus on fluoroquinolones [J]. Clin Infect Dis.2005,41 Suppl 2: S144-157.
  • 3Galatti L, Giustini SE, Sessa A, et al. Neuropsychiatric reactions to drugs: an analysis of spontaneous reports from general practitioners in Italy[J]. Pharmacol Res, 2005,51 (3) : 211-216.
  • 4Fish DN. Fluoroquinolonc adverse effects and drug interactions[J]. Pharmacotherapy [ J ]. 2001,21(10 Pt 2 ) : 253-272.
  • 5Reeves RR. Exacerbation of psychotic symptoms associated with gatifloxacin [ J]. Psychosomatics, 2007,48 ( 1 ) : 87.
  • 6Bazignan A,Thiessant F, Miremont G, et al. Psychiatric adverse effects of fluoroquinolone: review of cases from the French pharmacologic surveillance database[J]. Rev Med Interne,2006,27(6):448-452.
  • 7Bharal N, Pillai KK, Vohora D. Effects of sparfloxacin on CNS functions and urinary hydroxyproline in mice [ J ]. Pharmacol Res, 2006, 54 ( 2 ) :111-117.
  • 8Bharal N, Gupta S, Khurana S, et al. Anxiogenic and proconvulsant effect of gatifloxacin in mice[J]. Eur J Pharmacol,2008,580(1-2) : 130-134.
  • 9Reti IM, Davydow DS. Electroconvulsive therapy and antibiotics: a case report [J]. J ECT, 2007,23 ( 4 ) : 289-290.
  • 10Andriole VT. The quinolones, past, present, and future [ J ]. Clin Infect Dis,2005,41 Suppl 2: S113-119.

共引文献45

同被引文献34

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部